Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Rain
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
149.96
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
April 27, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
Via
Benzinga
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call
April 21, 2023
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
April 17, 2023
Via
Benzinga
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
April 11, 2023
Via
Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
April 05, 2023
Via
Benzinga
Why Legend Biotech Stock Is Having Its Best Month Yet
April 25, 2023
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.
Via
MarketBeat
3 Pharma Stocks That Could See a Surge in Demand in 2023
April 24, 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead
Via
InvestorPlace
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
April 20, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
April 19, 2023
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
March 21, 2023
Via
Benzinga
Alnylam Pharmaceuticals's Return On Capital Employed Insights
February 27, 2023
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
February 24, 2023
Via
Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
April 12, 2023
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...
Via
Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
April 04, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
March 13, 2023
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.
Via
InvestorPlace
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
March 08, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
March 03, 2023
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all...
Via
Benzinga
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
March 01, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
February 23, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
February 21, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
January 08, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Growth Stocks That Could Rocket Higher in 2023
January 06, 2023
Upcoming binary events could push these stocks to new all-time highs.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
Via
Benzinga
Alnylam Announces Updates to its Board of Directors
January 05, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.